Conclusions The present study establishes for the first time that the elevation of plasma ET in severe human CHF represents principally elevation of big-ET. Second, ET is present in healthy and failing myocardia, and its activity by both immunohistochemistry and radioimmunoassay is not changed in CHF. Furthermore, the elevated plasma ET is characteristic of severe CHF and not asymptomatic or mild CHF. In addition, the degree of plasma elevation of ET correlates with the magnitude of alterations in cardiac hemodynamics and functional class. The present study confirms and extends previous investigations of ET in human CHF and establishes the evolution of circulating and local cardiac ET in adaptations of CHF,222 major questions emerge regarding ET in human CHF. These include whether the elevation of immunoreactive ET in CHF represents the mature biologically active peptide, ET-1, or the less biologically active precursor big-ET. Second, as ET may augment myocardial contractility and stimulate myocardial cell hypertrophy,57 the presence, localization, distribution, and cardiac tissue molecular forms of ET require elucidation. Finally, although previous work has established that plasma ET is elevated in severe CHF, it remains to be established whether circulating ET is increased at the earliest stage of CHF in patients with asymptomatic left ventricular dysfunction (ALVD) and thus be a marker and/or participant in early and/or late CHF.
The current investigation was therefore undertaken in human heart failure to address the following hypotheses. (1) Human heart failure results in elevation of both mature ET-1 and the less biologically active precursor big-ET. (2) ET is present in healthy and failing human atrial and ventricular myocardia. (3) Circulating ET is increased only in advanced CHF and not in asymptomatic patients and parallels alterations in cardiac hemodynamics. To address these hypotheses, we used cardiac catheterization, myocardial biopsy, radioimmunoassay (RIA) analysis, immunohistochemical staining (IHCS), and gel permeation chromatography (GPC) to define the extent and molecular forms of plasma and cardiac ET in humans with ALVD and chronic CHF, including end-stage CHF.
Methods Subject Selection
Forty subjects (30 men and 10 women; average age, 64+5 years) were investigated. CHF patients were classified by New York Heart Association (NYHA) functional class criteria according to their cardiac symptoms after a complete physical examination and laboratory evaluation at the Mayo Clinic. The following class distributions resulted: NYHA class I (n=14; mean age, 61±3 years), NYHA class II (n=5; mean age, 62±3 years), NYHA class III (n=7; mean age, 69±2 years), NYHIA class IV (n=8; mean age, 65±4 years), and six control subjects (mean age, 61±4 years). The etiologies of CHF included idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Exclusion criteria included individuals with renal failure (serum creatinine > 176 gmol/L), abnormal liver function tests, significant valvular heart disease, atrial fibrillation, and frequent premature ventricular contractions. All severe CHF patients were on drug treatment, including digitalis, diuretics, and/or vasodilators. Left ventricular ejection fraction (LVEF) was determined by echocardiography or radionuclide angiography. Left ventricular end-diastolic volume was determined as well in those patients who underwent radionuclide angiography. All studies were performed with the patient in the supine position. Three ECG leads were monitored continuously. For radionuclide angiography, patients' red blood cells were labeled using 30 mCi of 9'Tc and using the modified in vivo procedure of Callahan et al. 23 Cardiac imaging was obtained with a small-field gamma camera (Picker Dyna Mo) in the left anterior oblique view by conventional consecutive R-wave gating and collected at 20 frames per cardiac cycle. A blood sample was obtained for cardiac volume determinations. Radionuclide data were processed using a commercially available computer and software (Medical Data Systems) and previously reported techniques. 24 The left ventricular region of interest was identified in each frame using a second derivative technique. A background region was chosen 5 pixels lateral to the left ventricular systolic region. LVEF was calculated from the background-corrected left ventricular counts-versus-time curve. End-diastolic and end-systolic volumes were determined using a count-based method25 and a previously reported regression equation from the Mayo Clinic Diagnostic Nuclear Medical Laboratory.26 Correlation coefficients for end-diastolic and end-systolic volumes determined by radionuclide angiograms compared with contrast ventriculography have been previously reported as 0.85 and 0.94, respectively.27 The end-diastolic volume index was determined by dividing end-diastolic volume by body surface area. For LVEF by echocardiography, the LVEF at rest was calculated by means of the left ventricular systolic and diastolic dimensions measured on the two-dimensional derived M-mode tracing in the majority of patients. When no adequate measurements could be obtained, a visual estimation of the LVEF was used. Techniques and methods have been previously reported at this institution.28629 Venipuncture for measurement of ET was performed while each patient was in the supine position. Six individuals with a resting ejection fraction of .50% and with no detectable cardiac disease served as the control group.
Healthy and CHF Subjects for Cardiac Tissue Characterization
Cardiac tissue was obtained from six patients (five men and one woman; average age, 49±2 years) with end-stage heart failure undergoing cardiac transplantation at the Mayo Clinic. Venous plasma samples from these patients were obtained before the transplantation procedure. Cardiac tissue included both atria and ventricles. Tissue samples were immediately placed in liquid nitrogen and stored at -70°C until further processing occurred. Cardiac tissue from both atria was harvested from healthy donor hearts at the time of transplantation and processed in an identical manner.
Quantitation of Plasma and Tissue ET
Plasma and tissue ET was determined by the ET-1,2[l`IJ assay system (Amersham Intermational, Amersham, UK) as previously described.13 Briefly, plasma was taken from chilled potassium EDTA tubes after centrifugation at 2500 RPM at 4°C and frozen at -20°C until assay. Cardiac tissue was immediately placed in liquid nitrogen and stored at -70°C until further processing was performed. Cardiac tissue was pulverized, boiled for 5 minutes in 10 vol of 1 mol/L acetic acid/20 mmol/L hydrochloric acid solution to abolish intrinsic proteolytic activity and then homogenized. The homogenate was centrifuged for 30 minutes at 15 000 rpm at 4°C. The supernatant was then stored at -20°C and analyzed by a specific RIA. The recovery of the extraction procedure was 81%, as determined by addition of synthetic ET to plasma, and interassay and intra-assay variations were 9% and 5%, respectively. The cross-reactivity of the assay to big-ET is 37%; ET-2, 100%; and ET-3, <1%.
Gel Permeation Chromatography Analysis ET was characterized from nonextracted plasma by a P-6 (Bio-Rad Laboratories, Richmond, Calif) gel filtration column (lx 13 cm). Plasma (500 ,uL) was applied to the column and eluted with 0.5 mol/L acetic acid buffer. Fractions of 0.5 mL were collected and dried by savant speedvac. The concentration of ET in each fraction was determined by RIA as previously described.13 The P-6 column was calibrated with synthetic 111 ET-1 and 1I big-ET (Peninsula Laboratory, Belmont, Calif). Fig 1 represents the calibration of the P-6 column with 'I ET-1 and 'I big-ET. Big-ET was eluted in fractions 5 to 8 (peak at fraction 6), and ET-1 was eluted in fractions 7 to 17 (peak at fraction 12). Total ET recovery was determined by adding the concentrations of each fraction (5 through 17) after subtraction of the background ET (2 pg per fraction). The mean column recovery of total ET was 86%.
Immunohistochemical Staining IHCS for ET was performed in cardiac tissue taken from healthy and severe CHF subjects. IHCS was performed in atrial and ventricular samples from healthy cardiac tissue and CHF patients. Atrial sections were taken from the appendages and free walls of both atria. Full-thickness sections of human ventricular myocardium were obtained from the middle third of the free wall of both the left and right ventricles from failing hearts. The healthy human right ventricular endocardial tissues were obtained from healthy donor heart during cardiac transplantation. Tissue was dehydrated and embedded in paraffin, and sections were cut to a 5 -,um thickness. The presence of cardiac ET was assessed using a previously described 
Statistical Analysis
Results of the quantitative studies are expressed as mean±SEM. Statistical comparisons within each group were performed by using ANOVA for repeated measures followed by Fisher's least significant difference test of repeated measures when appropriate, and comparisons between groups were performed by using factorial ANOVA followed by Fisher's least significant difference test of repeated measures. Statistical significance was accepted for P<.05.
Results
Fig 2 illustrates the hemodynamic characteristics of our patient population. LVEF was significantly decreased in asymptomatic, mild, and moderate left ventricular dysfunction (NYHA class I, II, and III) and was further decreased in severe CHF (NYHA class IV). Cardiac index was significantly decreased and left ventricular end-diastolic volume index was significantly increased in moderate and severe CHF (NYHA class III and IV). Fig 3 illustrates (Fig 4A) and from a patient with severe CHF (NYHA class IV) (Fig 4B) . This figure demonstrates that the only ET isoform in healthy subjects is mature ET-1, the 21-amino-acid biologically active peptide, whereas both mature ET-1 and its precursor big-ET, the 38-amino-acid prohormone, are present in plasma in patients with severe CHF. Fig 5 demonstrates the absolute values of plasma ET-1 and big-ET in healthy and CHF subjects (n=4 in each group). As shown in this figure, no circulating big-ET was detected by GPC in healthy subjects (n=4). However, big-ET represented 62±7% (14.6±2.4 pg/mL) and ET-1 represented 38±5% (8.6±1.2 pg/mL) of total immunoreactive plasma ET among the severe heart failure group (n=4). Table 1 IHCS of atrial and ventricular myocardia for ET from a representative healthy heart and a severe failing heart is illustrated in Fig 7. ET immunoreactivity was present at similar intensities in both healthy and failing hearts in atrial and ventricular myocardia and located less predominantly in the perinuclear region of cardiac myocytes. ET IHCS scores, percentage distribution (percent positive staining area), and tissue concentrations are reported in Table 2 . No differences were observed in these measured parameters between healthy and CHF hearts. Fig 8 illustrates This would be consistent with a role for ET-1 in CHF as functioning by paracrine and autocrine mechanisms. actions, which include enhanced inotropic action, mito- 
